Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 4, 2008, Pages 601-606

  Corona, G ^a   Vaccher, E ^a   Sandron, S ^a   Sartor, I ^a   Tirelli, U ^a   Innocenti, F ^b   Toffoli, G ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; APC; DIDANOSINE; DOXORUBICIN; GLUCURONIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LAMIVUDINE; LOPERAMIDE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; TENOFOVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

ADENINE; ADULT; AGED; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CAMPTOTHECIN; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PYRIMIDINONES; RITONAVIR; SARCOMA, KAPOSI;

EID: 40949156763     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100330     Document Type: Article

References (37)

1. Dal Maso, L., Serraino, D. & Franceschi, S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur. J. Cancer 37, 1188-1201 (2001).
2. Palella, F.J. Jr. et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 43, 27-34 (2006).
3. Sgadari, C., Monini, P., Barillari, G. & Ensoli, B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol. 4, 537-547 (2003).
4. Ikezoe, T. et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 64, 7426-7431 (2004).
5. Pomerantz, R.J. & Horn, D.L. Twenty years of therapy for HIV-1 infection. Nat. Med. 9, 867-873 (2003).
6. Flexner, C. HIV-protease inhibitors. N. Engl. J. Med. 338, 1281-1292 (1998).
7. Gutmann, H., Fricker, G., Drewe, J., Toeroek, M. & Miller, D.S. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. 56, 383-389 (1999).
8. Storch, C.H., Theile, D., Lindenmaier, H., Haefeli, W.E. & Weiss, J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73, 1573-1581 (2007).
9. de Maat, M.M., Ekhart, G.C., Huitema, A.D., Koks, C.H., Mulder, J.W. & Beijnen, J.H. Drug interactions between antiretroviral drugs and comedicated agents. Clin. Pharmacokinet. 42, 223-282 (2003).
10. Bower, M., Palmieri, C. & Dhillon, T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr. Opin. Infect. Dis. 19, 14-19 (2006).
11. Vaccher, E. et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 91, 155-163 (2001).
12. Fichtenbaum, C.J. & Gerber, J.G. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. 41, 1195-1211 (2002).
13. Fumagalli, L. et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother. Pharmacol. 45, 495-501 (2000).
14. Nannan, P.V. et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma - drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother. Pharmacol. 43, 516-519 (1999).
15. Toffoli, G. et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann. Oncol. 15, 1805-1809 (2004).
16. Antoniou, T. & Tseng, A.L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin. Pharmacokinet. 44, 111-145 (2005).
17. King, J.R., Wynn, H., Brundage, R. & Acosta, E.P. Pharmacokinetic enhancement of protease inhibitor therapy. Clin. Pharmacokinet. 43, 291-310 (2004).
18. Oldfield, V. & Plosker, G.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 66, 1275-1299 (2006).
19. Fuchs, C., Mitchell, E.P. & Hoff, P.M. Irinotecan in the treatment of colorectal cancer. Cancer Treat. Rev. 32, 491-503 (2006).
20. Vaccher, E., Di Gennaro, G., Simonelli, C., Schioppa, O. & Tirelli, U. Evidence of activity of irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. AIDS 19, 1915-1916 (2005).
21. Mathijssen, R.H. et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7, 2182-2194 (2001).
22. Kehrer, D.F., Mathijssen, R.H., Verweij, J., de Bruijn, P. & Sparreboom, A. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 20, 3122-3129 (2002).
23. Slatter, J.G. et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab. Dispos. 28, 423-433 (2000).
24. Drewe, J., Gutmann, H., Fricker, G., Torok, M., Beglinger, C. & Huwyler, J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 57, 1147-1152 (1999).
25. Iyer, L. et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002).
26. Zhang, D., Chando, T.J., Everett, D.W., Patten, C.J., Dehal, S.S. & Humphreys, W.G. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33, 1729-1739 (2005).
27. Rotger, M. et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192, 1381-1386 (2005).
28. Zucker, S.D. et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. USA 98, 12671-12676 (2001).
29. Innocenti, F. & Ratain, M.J. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7, 1211-1221 (2006).
30. Sai, K. et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501-515 (2004).
31. Toffoli, G. et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24, 3061-3068 (2006).
32. Shimada, Y. et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol. 11, 909-913 (1993).
33. World Medical Association, General Assembly 1964-2004. Ethical principles for medical research involving human subjects (The World Medical Association, Ferney-Voltaire, France, 2007) 〈http://www.wma.net/e〉.
34. Krigel, R.L., Laubenstein, L.J. & Muggia, F.M. Kaposi's sarcoma: a new staging classification. Cancer Treat. Rep. 67, 531-534 (1983).
35. Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
36. Ma, Q. et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin. Drug Metab. Toxicol. 1, 473-485 (2005).
37. Saltz, L.B. et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 14, 2959-2967 (1996).